We analyzed the progression free interval (PFI) and overall survival (OS) of breast cancer and melanoma patients according to the expression level of SLAMF6. In the breast cancer cohort, PFI and OS was significantly longer in the high SLAMF6 group than in the low SLAMF6 group (PFI; p = 0.0011, OS; p = 0.0019) (Fig. 1A). Here, SLAMF6 is linked to melanoma.